Sight Diagnostics is a medical device company bringing affordable, accurate diagnostics to the point-of-care.
Sight Diagnostics aims to transform health systems and patient outcomes through accurate and pain-free blood diagnostic testing.
Sight Diagnostics was founded in 2011 by Yossi Pollak and Daniel Levner. The company is headquartered in Tel Aviv, Israel, with offices in Silicon Valley and London.
Sight is committed to providing rapid and accurate blood tests to aid health professionals in diagnosing and treating patients around the world.
Sight’s technology developed over almost a decade of research, represents breakthrough innovations in diagnostic methodology. Sight’s first product, Parasight, has been used to detect malaria in almost 1 million tests across 24 countries.
Sight’s latest blood analyser, OLO, performs a Full Blood Count, the most commonly ordered blood test, in minutes. OLO’s technology combines computer vision and AI to digitise each blood sample into more than 1,000 high resolution images.
Sight is backed by Longliv Ventures, OurCrowd, Go Capital, CK Hutchison Group, New Alliance Capital, Anatomy Technology Fund and others. The company raised $71M in Series D round on Jul 27, 2020. This brings Sight's total funding to $123.8M to date.